Candriam S.C.A. Buys 117,331 Shares of Bicycle Therapeutics PLC Sponsored ADR $BCYC

Candriam S.C.A. grew its holdings in Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) by 10.8% in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,205,207 shares of the company’s stock after buying an additional 117,331 shares during the quarter. Candriam S.C.A. owned 1.74% of Bicycle Therapeutics worth $10,232,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently made changes to their positions in BCYC. Barclays PLC increased its position in shares of Bicycle Therapeutics by 878.3% during the 4th quarter. Barclays PLC now owns 2,612 shares of the company’s stock worth $37,000 after purchasing an additional 2,345 shares in the last quarter. GAMMA Investing LLC boosted its stake in shares of Bicycle Therapeutics by 879.5% in the 1st quarter. GAMMA Investing LLC now owns 8,982 shares of the company’s stock valued at $76,000 after purchasing an additional 8,065 shares during the last quarter. Exchange Traded Concepts LLC boosted its stake in shares of Bicycle Therapeutics by 90.3% in the 1st quarter. Exchange Traded Concepts LLC now owns 12,764 shares of the company’s stock valued at $108,000 after purchasing an additional 6,057 shares during the last quarter. Cerity Partners LLC bought a new position in shares of Bicycle Therapeutics in the 1st quarter valued at about $113,000. Finally, Tocqueville Asset Management L.P. boosted its stake in Bicycle Therapeutics by 24.5% during the 1st quarter. Tocqueville Asset Management L.P. now owns 18,300 shares of the company’s stock worth $155,000 after acquiring an additional 3,600 shares during the last quarter. Institutional investors and hedge funds own 86.15% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the stock. Needham & Company LLC reissued a “buy” rating and set a $29.00 price objective on shares of Bicycle Therapeutics in a research note on Friday, May 2nd. Barclays reduced their price objective on shares of Bicycle Therapeutics from $40.00 to $15.00 and set an “overweight” rating on the stock in a research note on Thursday, May 1st. JMP Securities reduced their price objective on shares of Bicycle Therapeutics from $22.00 to $10.00 and set a “market outperform” rating on the stock in a research note on Tuesday, August 12th. Royal Bank Of Canada set a $27.00 price objective on shares of Bicycle Therapeutics and gave the stock an “outperform” rating in a research note on Monday, August 11th. Finally, B. Riley reduced their price objective on shares of Bicycle Therapeutics from $17.00 to $14.00 and set a “neutral” rating on the stock in a research note on Friday, May 2nd. Seven research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $22.22.

Bicycle Therapeutics Stock Up 0.9%

Shares of BCYC stock opened at $7.09 on Friday. Bicycle Therapeutics PLC Sponsored ADR has a 12 month low of $6.10 and a 12 month high of $28.67. The company’s fifty day simple moving average is $7.73 and its 200-day simple moving average is $8.67. The firm has a market cap of $490.98 million, a PE ratio of -2.02 and a beta of 1.44.

Bicycle Therapeutics (NASDAQ:BCYC) last released its earnings results on Friday, August 8th. The company reported ($1.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.95) by ($0.19). The company had revenue of $2.90 million for the quarter, compared to the consensus estimate of $9.43 million. Bicycle Therapeutics had a negative return on equity of 32.43% and a negative net margin of 1,257.00%. On average, equities analysts predict that Bicycle Therapeutics PLC Sponsored ADR will post -3.06 earnings per share for the current fiscal year.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.